NVCR - ノボキュア (NovoCure Limited)

NVCRのニュース

   NovoCure Limited (NASDAQ:NVCR) Is 22.21% Above Its 52-Week Low, But How Long Can It Continue?  2022/04/30 12:00:00 Marketing Sentinel
In last trading session, NovoCure Limited (NASDAQ:NVCR) saw 0.65 million shares changing hands with its beta currently measuring 0.85. Company’s recent per share price level of $76.58 trading at -$0.6 or -0.78% at ring of the bell on the day assigns it a market valuation of $8.58B. That closing price of NVCR’s stock is at … NovoCure Limited (NASDAQ:NVCR) Is 22.21% Above Its 52-Week Low, But How Long Can It Continue? Read More »
   Novocure (NVCR) Q1 2022 Earnings Call Transcript  2022/04/28 17:30:35 The Motley Fool
NVCR earnings call for the period ending March 31, 2022.
   NovoCure Limited''s (NVCR) Management on Q1 2022 Results - Earnings Call Transcript  2022/04/28 16:30:26 Seeking Alpha
NovoCure Limited (NASDAQ:NASDAQ:NVCR) Q1 2022 Earnings Conference Call April 28, 2022 8:00 AM ET Company Participants Ingrid Goldberg – Investor Relations Bill Doyle – Executive Chairman…
   NovoCure: Q1 Earnings Insights  2022/04/28 13:54:48 Benzinga
NovoCure (NASDAQ: NVCR ) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings NovoCure beat estimated earnings by 77.78%, reporting an EPS of $-0.04 versus an … Full story available on Benzinga.com
   NovoCure GAAP EPS of -$0.04 beats by $0.15, revenue of $137.55M beats by $3.26M  2022/04/28 11:06:38 Seeking Alpha
NovoCure press release (NVCR): Q1 GAAP EPS of -$0.04 beats by $0.15.Revenue of $137.55M (+2.1% Y/Y) beats by $3.26M.Gross margin for the quarter was 80%. As of March 31, 2022,…
   Novocure to Report Third Quarter 2021 Financial Results  2021/10/04 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced that it will report financial results for the third quarter 2021 on Thursday, October 28, 2021.
   Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China  2021/10/04 11:30:00 Intrado Digital Media
Final data collection is expected in the first half of 2022
   Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China  2021/10/04 11:30:00 Business Wire
ST. HELIER, Jersey & SHANGHAI--(BUSINESS WIRE)-- #GastricCancer--Novocure and Zai Lab announced that the last patient has been enrolled in a phase 2 pilot trial of TTFields plus chemotherapy in gastric cancer.
   Novocure To Test Its Tumor Treating Fields With Roche''s Tecentriq In Pancreatic Cancer  2021/09/14 12:34:37 Benzinga
Novocure Ltd (NASDAQ: NVCR ) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY ) to develop Tumor Treating Fields (TTFields) together with Roche''s atezolizumab in metastatic pancreatic ductal adenocarcinoma (mPDAC). The phase 2 study was designed to test the safety and efficacy of TTFields together with atezolizumab, gemcitabine, and nab-paclitaxel as Full story available on Benzinga.com
   Novocure in pact with Roche to test potential of Tumor Treating Fields in pancreatic cancer  2021/09/14 11:53:15 Seeking Alpha
   Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program  2021/07/15 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure today announced the recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research program.
   Novocure to Report Second Quarter 2021 Financial Results  2021/07/08 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced today that it will report financial results for the second quarter 2021 on July 29, 2021, before the U.S. financial markets open.
   NovoCure: High-Income Options Trade, Bullish Vertical Put Spread  2021/07/02 17:03:17 Seeking Alpha
   Analyzing NovoCure''s Unusual Options Activity  2021/07/02 16:24:01 Benzinga
Shares of NovoCure (NASDAQ: NVCR ) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved down to $184.64. Sentiment: BEARISH Option Type: TRADE Trade Type: CALL Expiration Date: 2021-09-17 Strike Price: $230.00 Volume: 253 Open Interest: 60 Three Indications Of Unusual Options Activity Exceptionally large volume (compared to historical averages) is one reason for which options market activity can be considered unusual. The volume of options activity refers to the number of contracts traded over a given time period. The number of contracts that have been traded, but not yet closed by either counterparty, is called open interest. A contract cannot be considered closed until there exists both a buyer and seller for it. Another indicator of unusual options activity is the trading of a contract with an expiration date in Full story available on Benzinga.com
   Arcturus wins bullish call on vaccine potential, Novocure downgraded in today''s analyst action  2021/07/02 13:15:18 Seeking Alpha

calendar